References:
- Ministerstvo ohoroni zdorov’ya Ukrayini (2007) Nakaz MOZ Ukrayini vId 19.03.2007 (http://www.ifp.kiev.ua/doc/staff/MOZ-128-19032007.pdf).
- Calò L., Passàli G.C, Galli J. (2011) Role of biofilms in chronic inflammatory diseases of the upper airways. Adv. Otorhinolaryngol., 72: 93–96. doi: 10.1159/000324622.
- Chang J.Y., Shim K.-N., Tae Ch.H. et al. (2017) Triple therapy versus sequential therapy for the first-line Helicobacter pylorі eradication. BMC Gastroenterol., 17: 16.
- Giamarellos-Bourboulis E.J., Pechère J.C., Routsi C. et al. (2008) Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin. Infect. Dis., 46(8): 1157–1164. doi: 10.1086/529439.
- Gogos C.A., Drosou E., Bassaris H.P., Skoutelis A. (2000) Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis., 181: 176–180.
- Heron M. (2007) Deaths: leading causes for 2004. Natl. Vital. Stat. Rep., 56(5): 1–95.
- Malfertheiner P., Megraud F., O’Morain C.A. et al.; European Helicobacter Study Group (2012) Management of Helicobacter pylori infection — the Maastricht IV/Florence Consensus Report. Gut, 61(5): 646–664. doi: 10.1136/gutjnl-2012-302084.
- Spyridaki A., Raftogiannis M., Antonopoulou A. et al. (2012) Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. Antimicrob. Agents Chemother., 56(7): 3819–3825. doi: 10.1128/AAC.05798-11.